the hormone FGF23, which regulates mineral and cardiovascular homeostasis. FGF23 is a b1-derived hormone whose principal function is to regulate phosphate and 1,25(OH) 2 D metabolism (21) (22) (23) (24) . Structural models show that the N-terminus of FGF23 and the KL2 domain of mKL 135 interact with FGF receptors (FGFRs) 1c, 3c, or 4, and the C-terminus of FGF23 binds to a pocket created by the KL1 and KL2 domains to form the active ternary canonical FGF23/FGFR/KL receptor complex (3, 25, 26) . Shed sKL 130 can also act as a circulating "on-demand, non-enzymatic scaffold" protein that regulates FGF23 signaling (3). The physiological effects of circulating FGF23 are mediated by activation of FGFRs complexed with transmembrane α-Klotho (i.e., canonical signaling) (25). The codependency of FGF23 and Klotho is supported by mouse genetic studies showing that Fgf23 -/and Kl -/mice are exact phenocopies, characterized by hyperphosphatemia, excess 1,25(OH) 2 D 3 , soft tissue calcifications, and early mortality (2, (27) (28) (29) . The nonredundant phenotypes are further supported by the fact that Kl -/mice are refractory to FGF23 effects (30-32), and compound mutant Fgf23 and Kl have nonadditive effects (27, (30) (31) (32) (33) .
Introduction
It is widely accepted that α-Klotho (KL) functions as an aging suppressor gene in mice (1) , largely based on a seminal publication showing that KL extends life span when transgenically overexpressed in mice (1) . Kl-transgenic (Kl Tg ) mice were created by overexpression of the Kl cDNA that encodes the transmembrane protein with KL1 and KL2 domains under control of the human elongation factor 1a (hEF1a) promoter. The development of a premature aging-like syndrome when Kl is disrupted in mice further supports the role of KL in longevity (2) . The KL gene generates 2 transcripts in mammals, a full-length KL mRNA that encodes a single-pass 135-kDa transmembrane cell surface protein with extracellular KL1 (Glu34 to Phe506) and KL2 (Leu515 to Ser950) domains (designated mKL 135 ) (3) . An alternative spliced mRNA that encodes only a KL1-like domain (sKL 70 ) is not translated in humans (4, 5) but is found in the mouse brain (6, 7) . Rather, mKL 135 undergoes ectodomain shedding by ADAM10 (a disintegrin and a metalloproteinase domain 10) and ADAM17 metalloproteinases to generate a circulating isoform of about 130 kDa (sKL 130 ) that contains the KL1 and KL2 domains (8, 9) . Soluble circulating Klotho (sKL) is detected in serum (10) , urine (11) , and cerebrospinal fluid (ref. 12 ; see supplemental data and Supplemental Figure 1 for nomenclature; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.132820DS1).
The increased longevity in Kl Tg mice was originally attributed to functions of sKL to inhibit insulin and insulin-like growth factor (IGF) signaling. This hypothesis is consistent with the fact that Klotho orthologs in Caenorhabditis elegans encode only KL1 domain-like proteins that inhibit DAF-2, which is homologous to IGF-1 signaling in mammals (13) . Additional studies found that sKL inhibits TNF-α, IGF-1, Wnt, and TGF-β signaling (1, (14) (15) (16) (17) (18) . In addition, sKL is proposed to bind to gangliosides containing α-2-3-sialyllactose in lipid rafts to inhibit PI3K signaling (19) , as well as regulate calcium-permeable transient receptor potential canonical type isoform 6 (TRPC6) channels (20) .
The mechanisms whereby KL exerts antiaging effects, however, warrant reexamination based on new knowledge that both transmembrane (mKL 135 ) and soluble Klotho (sKL 130 ) act as coreceptors for
Observations in transgenic α-Klotho (Kl) mice (Kl Tg ) defined the antiaging role of soluble Klotho (sKL 130 ). A genetic translocation that elevates sKL levels in humans is paradoxically associated with increased circulating fibroblast growth factor 23 (FGF23) levels and the potential of both membrane KL (mKL 135 ) and sKL 130 to act as coreceptors for FGF23 activation of fibroblast growth factor receptors (FGFRs). Neither FGF23 expression nor the contributions of FGF23, mKL 135 , and sKL 130 codependent and independent functions have been investigated in Kl Tg mice. In the current study, we examined the effects of Kl overexpression on FGF23 levels and functions in Kl Tg mice. We found that mKL 135 but not sKL 130 stimulated FGF23 expression in osteoblasts, leading to elevated Fgf23 bone expression and circulating levels in Kl Tg mice. Elevated FGF23 suppressed 1,25(OH) 2 D and parathyroid hormone levels but did not cause hypophosphatemic rickets in Kl Tg mice. Kl Tg mice developed low aldosterone-associated hypertension but not left ventricular hypertrophy. Mechanistically, we found that mKL 135 and sKL 130 are essential cofactors for FGF23-mediated ERK activation but that they inhibited FGF23 stimulation of PLC-γ and PI3K/AKT signaling. Thus, increased longevity in Kl Tg mice occurs in the presence of excess FGF23 that interacts with mKL and sKL to bias FGFR pathways.
Results
Klotho isoforms' expression in Kl Tg mice. First, we examined full-length (mKl 135 ) and alternatively spliced Kl (sKl 70 ) message expression in different tissues in wild-type and Kl Tg mice by real-time reverse transcription PCR (RT-PCR) (1) . Endogenous mKl 135 in wild-type mice was highly expressed in the kidney; low levels of mKl 135 transcripts were also detected in bone and bone marrow (50, 51) , as well as in heart, spleen, and liver ( Figure 1A ). In spite of the wide tissue expression of hEF1a promoter, we observed significant increases of mKl 135 transcripts, which represents the combination of the transgene and endogenous gene, only in the kidney and bone of Kl Tg mice compared with wild-type mice ( Figure 1A ). In Kl Tg mice, mKl 135 expression in other tissues, including bone marrow, heart, spleen, and liver, was similar to wild-type mice ( Figure 1A ). In addition, we found low levels of the alternatively spliced sKl 70 transcripts in the kidney, tibia, bone marrow, heart, spleen, and liver in wild-type mice ( Figure 1B , note different scale) and significant increases in sKl 70 transcripts in Kl Tg mice compared with wild-type mice in kidney, bone, and heart, suggesting that overexpression of mKl 135 may have altered sKl 70 mRNA expression or decay (5) .
Next, we examined expression of the mKL 135 (~135 kDa), sKL 130 (~130 kDa), and sKL 70 (~70 kDa) proteins by Western blot analysis ( Figure 1C ). The levels of expression of α-Klotho proteins were lower in wild-type mice but with bands consistent with mKL 135 or sKL 130 (KL1 and KL2) and sKL 70 (or sKL1 70 ) in the kidney ( Figure 1C ). We detected no other protein bands in other tissues (data not shown). In Kl Tg mice, we found strong bands consistent with increased expression of both mKL 135 or sKL 130 (KL1 and KL2) in the kidney. We also observed increased expression of sKL 70 or sKL1 70 in the kidney but to a lesser extent ( Figure 1C ). The 135-kDa band intensity was much greater than the 70-kDa band in the kidney in Kl Tg mice. The antibody used did not detect the KL2 fragment. We also found very weak bands consistent with mKL 135 or sKL 130 (KL1 and KL2) in the bone, heart, and liver in Kl Tg mice. Thus, the magnitude of the increase in mKL 135 and its tissue distribution were more limited than expected in Kl Tg mice, given the positive phenotypes affecting multiple organs reported in these mice.
Finally, to measure sKL protein levels in the serum, we performed coimmunoprecipitation (CoIP) with anti-Klotho KL1 rat mAb (KL-234) and used a validated ELISA. In Kl Tg mice, we detected an increase of Figure 1D ). In addition, serum sKL levels were more than 2-fold higher in Kl Tg mice compared with controls (Table 1) . Collectively, these studies demonstrate that Kl Tg mice have proportionately greater increase in serum sKL compared with tissue mKL 135 expression.
FGF23 expression in Kl Tg mice. Next, we examined the effects of overexpression of mKl 135 on Fgf23 expression. We examined Fgf23 message expression in various tissues ( Figure 1E ). Fgf23 is predominately expressed in bone and bone marrow of wild-type mice, where Fgf23 is known to be expressed in the osteoblasts/osteocytes and in endothelial cells of the bone marrow venous sinusoids, respectively (53) . We also detected lowlevels of Fgf23 transcripts in the heart and spleen but not in the kidney or liver of wild-type mice. In Kl Tg mice, we found a significant increase of Fgf23 transcripts in both bone and bone marrow samples but not in other tissues ( Figure 1E ). This was accompanied by a 2-fold elevation of serum FGF23 in the Kl Tg mice ( Table 1) .
To explore the relative contributions of α-Klotho isoforms to the increased Fgf23 expression in the Kl Tg mice, we cotransfected cDNAs for each of the mKl 135 , sKl 130 (KL1 and KL2), and sKl 70 isoforms along with Fgf23 reporter construct in MC3T3-E1 osteoblasts. Surprisingly, only transient overexpression of mKl 135 isoform showed stimulatory effects on Fgf23 reporter activity compared with empty vector control ( Figure 1F ). Neither sKl 130 (KL1 and KL2) nor sKl 70 stimulated Fgf23 reporter activity in this in vitro model ( Figure  1F ), suggesting canonical activation of FGFR1 and membrane α-Klotho overexpression in osteoblasts may account for the increased FGF23 levels in the Kl Tg mice.
Serum parameters and kidney gene profiles in Kl Tg mice. We then examined biological effects of excess FGF23, mKL 135 , and sKL in Kl Tg mice. We did not attempt to verify the increased longevity and other antiaging phenotypes that are well documented in the Kl Tg model (1) but focused on FGF23-dependent effects. The 2-fold increase in FGF23 was not associated with alterations in serum phosphate and calcium, which were not different between wild-type and Kl Tg mice (Table 1 ). However, both parathyroid hormone (PTH) and 1,25(OH) 2 D levels were significantly reduced in the Kl Tg mice ( Table 1 ). In addition, we found that serum aldosterone levels in the Kl Tg mice were much lower than those in wild-type control mice. These biochemical changes are consistent with known effects of FGF23 to target FGFR/KL binary complexes Data are mean ± SD from 8-10 serum samples of 8-week-old individual mice. A P < 0.05 versus wild-type. B P < 0.01 versus wild-type. Data are mean ± SD from 8-10 kidneys of 8-week-old individual mice and expressed as the fold changes relative to the housekeeping gene β-actin subsequently normalized to control mice. A P < 0.05 versus wild-type. B P < 0.001 versus wild-type.
in the proximal tubule to suppress 1,25(OH) 2 D production (28) and in the distal tubule to increase sodium reabsorption (54) , as well as possible effects of FGF23 and α-Klotho to suppress PTH expression and secretion in the parathyroid gland (55, 56) . In addition, the Kl Tg mice exhibited alterations in FGF23-responsive genes in the kidney that regulate 1,25(OH) 2 D metabolism, including decrements in Cyp27b1, which controls synthesis, and increments in Cyp24a1, which controls catabolism of 1,25(OH) 2 D and sodium chloride cotransporter (NCC), which maintains body Na + and K + homeostasis. The sodium/phosphate cotransporters located in the proximal convoluted tubule were not changed whereas the downstream sodium-dependent phosphate cotransporter 2c (Npt2c) located in the proximal straight tubule was decreased 2-fold in the Kl Tg mice ( Table 2 ). Failure to reduce the upstream Npt2a mRNA may account for the absence of hypophosphatemia and may reflect the effects of reduced PTH that offset the increased FGF23 renal effects. There were no differences in Fgfr1 transcripts between wild-type and Kl Tg mice.
Cardiovascular parameters and heart gene profiles in Kl Tg mice. FGF23 excess can induce LVH through direct activation of FGFR4 in the heart and indirect effects on the kidney to increase sodium reabsorption, leading to hypertension (46, 47, 57) . In contrast, sKL can prevent LVH caused by angiotensin II-induced cardiac hypertrophy (58, 59) . Therefore, we investigated whether Kl Tg mice exhibited cardiovascular abnormalities.
We observed no significant changes of heart weight/body weight (HW/BW) or heart weight/femur length (HW/FL) ratio between Kl Tg and wild-type control mice ( Figure 2 , A-C). Echocardiographs showed that Kl Tg mice had no differences in left ventricular (LV) mass, left ventricular posterior wall (LVPW) thickness at end-systole, LVPW at end-diastole, and left ventricular ejection fraction (LVEF) at baseline compared to wild-type mice (Figure 2 , D-G). Consistent with the absence of LVH in Kl Tg mice, real-time RT-PCR analysis revealed that the heart in the Kl Tg mice displays downregulation of LVH-related genes' expression (i.e., α-SMA, ANP, BNP, and BMHC) as well as cardiac fibrosis and epithelial-mesenchymal transition genes' expression (i.e., ColI, CTGF, Vimentin, TGFB, and Snail1) ( Table 3) .
In contrast, blood pressure, including systolic BP, diastolic BP, and mean BP, were significantly higher in Kl Tg compared with wild-type mice ( Figure 2H ). Thus, neither elevated FGF23 level or blood pressure induced LVH in Kl Tg mice, consistent with the purported protective function of α-Klotho in the heart (Table 3) .
Skeletal phenotypes and bone gene profiles in Kl Tg mice. Because of recent studies showing that α-Klotho inhibits bone mineralization (50, 51) , we investigated the bone phenotype of Kl Tg mice. At 8 weeks of age, the gross appearance and BW of wild-type and Kl Tg mice were indistinguishable. Compared to wild-type mice, Kl Tg mice exhibited no abnormalities in bone mass as evidenced by normal bone mineral density (BMD) in both male and female adult mice ( Figure 3A ). Micro-CT analysis revealed that there was no difference in trabecular bone volume, cortical bone thickness, or growth plate appearance of Kl Tg mice compared to wild-type mice ( Figure 3B ). Consistent with a normal bone mass and structure by BMD and micro-CT analysis, we found that there was no change in periosteal MAR between wild-type and Kl Tg mice ( Figure 3C ), indicating a normal bone formation rate in Kl Tg mice.
Next, we examined by real-time RT-PCR the expression levels of a panel of osteoblast lineage-, osteoclast-, chondrocyte-, and adipocyte-related mRNAs from the femurs of 8-week-old wild-type and Kl Tg mice ( Table 4 ). The Kl Tg mice did exhibit higher expression of mKl 135 and Fgf23 transcripts, as we described above. However, we did not observe significant alterations in osteoblast lineage-, osteoclast-, or chondrocyte-related gene expression (Table 4 ). We found significant reductions of only Osteocalcin and Osteopontin mRNA levels in the Kl Tg mice compared with wild-type mice. Unexpectedly, Pparg, an adipocyte transcription factor, and adipocyte markers, including lipoprotein lipase (Lpl) and adipocyte fatty acid-binding protein 2 (aP2), were significantly increased in the long bones of Kl Tg mice, indicating overexpression of mKl 135 enhanced adipogenesis in bone marrow of Kl Tg mice. These findings are consistent with the promotion of adipogenesis by mKl 135 (60, 61) .
Compound Fgf23 knockout and Kl Tg mice. To look for a survival benefit in Kl Tg mice and for FGF23-independent effects, we overexpressed mKl 135 in Fgf23-deficient mice. Kl Tg Fgf23 +/mice were mated with Kl Tg Fgf23 +/mice to generate wild-type, Kl Tg , Fgf23 -/-, and Kl Tg Fgf23 -/with the expected Mendelian frequency. Kl Tg mice developed normally, identically to wild-type littermates during 8 weeks. In contrast, Fgf23 -/mice exhibited growth retardation at 8 weeks of age; their body size and BW were significantly smaller and Data are mean ± SD from 8-10 kidneys of 8-week-old individual mice and expressed as the fold changes relative to the housekeeping gene β-actin subsequently normalized to control mice. A P < 0.05 versus wild-type. B P < 0.01 versus wildtype. C P < 0.001 versus wild-type.
lower, respectively, than wild-type littermates ( Figure 4A ). The Fgf23 -/mice began to die after weaning at 4 weeks of age; no mice could survive beyond 10 weeks. Transferring a Fgf23-null background onto Kl Tg mice did not improve BW and percentage of survival in compound Fgf23-null and Kl Tg mice ( Figure 4B ), suggesting that overexpression of mKl 135 alone could not rescue the Fgf23-null phenotype without the FGF23 ligand and that non-FGF23-dependent effects of mKL 135 cannot be examined in this study. FGF23-dependent function of α-Klotho isoforms in vitro. Finally, we tested the "on-demand" hypothesis that sKL can support FGF23 activation of FGFRs by comparing the ability of mKL 135 and sKL 130 to act as cofactors for FGFR-coupled activation of ERK, PLC-γ, and PI3K/AKT pathways (48) . For these studies, HEK293T cells, which endogenously express FGFRs but not α-Klotho (62), were transfected with either empty vector or human α-Klotho isoform cDNAs (mKL 135 , sKL 130 , sKL1 70 , sKL2 60 , or sKL 70 ). An ERK reporter construct was used to measure the FGF23/FGFR/KL-ERK signal transduction system in vitro ( Figure  5A ). The KL-transfected cells were treated with recombinant FGF23 (rFGF23) and heparan sulfate (HS) to examine, respectively, the α-Klotho and HS-dependent FGFR activation by FGF23. We also cotransfected HEK293T cells with TACE cDNA, which encodes ADAM17, to test the effects of ectodomain shedding on mKL 135 functions. In addition, the HEK293T cells transfected with ERK reporter were treated with human recombinant Klotho (rKL) protein to compare to the corresponding transfected sKL 130 cDNA, in the presence of rFGF23 and HS.
As shown in Figure 5B , HEK293T cells overexpressing mKL 135 exhibited a robust (about 8-10 fold) increase in ERK activation in response to FGF23 plus HS, consistent with the known canonical FGF23/ FGFR/mKL 135 signaling pathway. The response to sKL 130 , however, resulted in a significantly smaller increase in ERK activity (about 2-3 fold) in response to FGF23. Thus, we show for the first time to our knowledge quantitative differences between membrane and circulating Klotho's ability to activate ERK signaling. HEK293T cells transfected with sKL1 70 , sKL2 60 , or sKL 70 isoforms exhibited no enhancement of FGF23 stimulation of ERK activity, indicating that KL1 and KL2 domains are required for FGF23 activation of FGFR/ERK signaling, as suggested by the 3D structural data (3). Overexpression of ADAM17 significantly reduced the effects of cotransfected mKL 135 to enhance FGF23-mediated ERK activation, consistent with effects of ectodomain shedding to reduce canonical FGF23/FGFR/mKL 135 -dependent ERK signaling ( Figure 5C ).
Next we tested the effects of rKL in vitro. As previously reported (62), recombinant FGF23 plus HS exhibited a low but significant stimulation of ERK reporter activity in the absence of rKL. Treatment of rKL led to a modest stimulation of FGF23 signaling (about 2-3 fold, Figure 5D ) similar to sKL 130 transient transfection, suggesting that rKL (KL1 and KL2) can only partially reconstitute canonical FGF23/FGFR/ mKL 135 signaling imparted by mKL 135 . These data suggest that mKL 135 with its transmembrane and intact KL1 and KL2 domains is necessary for optimal FGF23 activation of FGFRs, whereas neither the KL1 nor the KL2 domain is sufficient to support canonical FGF23 signaling. All α-Klotho isoforms containing KL1 domain significantly reduced both basal and TNF-α-or FGF23-mediated NF-κB activation, whereas KL2 had no effect at all ( Figure 5 , E and F). These findings suggest that the inhibitory effects on both TNF-α and FGF23 signaling reside in the KL1 domain.
To explore why KL1 failed to augment FGF23 activation of ERK, but inhibited NF-κB activation, we examined the effects of KL isoforms on FGFR activation of PLC-γ and PI3K/AKT signaling pathways in response to FGF23. PLC-γ signaling, which is upstream of NF-κB, has been implicated in FGF23-induced LVH (48) . Surprisingly, we found that FGF23 activated both PLC-γ and PI3K/AKT signaling pathways in HEK293T cells in the absence of transfected KL isoforms ( Figure 6 ). Moreover, transfection of mKL 135 , sKL 130 , sKL 70 , or sKL1 70 containing KL1 domain inhibited FGF23 activation of PLC-γ and PI3K/AKT signaling pathways ( Figure 6 ). sKL2 60 transfection did not inhibit FGF23 activation of PLC-γ and PI3K/AKT, indicating that this inhibitory activity resides in the KL1 fragment ( Figure 6 ). Collectively, our findings identify both the obligate coreceptor function of KL that is required for FGF23 activation of ERK and a potentially previously unrecognized function of KL to block FGF23-induced PLC-γ and PI3K/AKT signaling.
Discussion
In the current study, we provide a rigorous reassessment of the Kl Tg mouse longevity model in light of new knowledge of FGF23 and α-Klotho codependent signaling. This reexamination is warranted because the seminal observations in Kl Tg that gave rise to the idea that shed α-Klotho is an antiaging hormone did not adequately consider the potential of α-Klotho to stimulate FGF23 production by osteoblasts in bone or the impact of the interdependent functions of FGF23, mKL 135 , and sKL on cell signaling.
We found that the Kl Tg mouse model is not a pure model of sKL excess. Rather, Kl Tg is a unique model that has excess mKL 135 in multiple tissues and increased circulating concentrations of both FGF23 and sKL 130 . The phenotype of Kl Tg , therefore, is likely a composite of increased canonical FGF23/FGFR/ mKL 135 signaling as well as FGF23-dependent and -independent effects of sKL 130 .
Kl Tg mice had an increase in FGF23 expression in bone and elevated serum FGF23 levels, which confounds the original interpretation of this as a pure model of sKL excess (1). In addition, we found that transfection Table 4 Data are mean ± SD from 8-10 tibias of 8-week-old individual mice and expressed as the fold changes relative to the housekeeping gene β-actin subsequently normalized to control mice. A P < 0.05 versus wild-type. B P < 0.01 versus wild-type.
. Gene expression profiles in bone in 8-week-old mice
of membrane Klotho, but not sKL, activates Fgf23 promoter activity in osteoblast cultures, possibly because of its greater FGF23-mediated induction of ERK activation (see below). Possibly, elevations in α-Klotho can stimulate FGF23, as was previously suggested by effects of a translocation in α-Klotho gene in humans that increased α-Klotho expression and sKL levels, leading to increased circulating FGF23, hyperparathyroidism, and hypophosphatemic rickets (49) . Overexpression of sKL 130 with an adeno-associated virus in mice also leads to a dose-dependent hypophosphatemia and elevation of FGF23 levels (52, 63) . We failed, however, to observe hypophosphatemia in Kl Tg mice but observed suppression of 1,25(OH) 2 D, increased Cyp24a1, and reduced Cyp27b1, consistent with the combined actions of canonical FGF23/FGFR/mKL 135 (21) (22) (23) (24) and PTH in the kidney. The lack of FGF23-mediated hypophosphatemia may be due to normal expression of Npt2a in the kidney due to the offsetting effects of reduced PTH to increase renal phosphate reabsorption in Kl Tg mice. The observed reduction in PTH in Kl Tg mice was unexpected because hyperparathyroidism was observed in humans with the translocation leading to increased sKL, and elevations in FGF23 are associated with increased PTH in Hyp mice and patients with X-linked hypophosphatemia. However, α-Klotho is normally expressed in the parathyroid gland, and studies showing that FGF23 activation of FGFR/mKL 135 signaling suppresses PTH (55, 56, 64) are consistent with our results.
Surprisingly, despite the purported role of FGF23 and α-Klotho to inhibit osteoblast function and bone mineralization, we did not observe any evidence of rickets, impaired bone formation, or defective mineralization in Kl Tg mice, which differs from rickets and osteomalacia reported in human α-Klotho translocation with elevated FGF23 (49) . The lack of hypophosphatemia, reductions in PTH, and wide tissue expression of α-Klotho may contribute to the failure to observe effects of FGF23 and α-Klotho on bone in Kl Tg mice. Last, the lack of LVH and the prior reports of improved survival of Kl Tg mice are discordant with the presence of hypertension and elevated FGF23 that we found in these mice (1) . FGF23-induced hypertension and cardiac toxicity is thought to be mediated in part by renal effects to stimulate sodium reabsorption and suppress renal angiotensin I converting enzyme 2 and α-Klotho expression, leading to low levels of aldosterone, hypertension, and LVH (47, 65) . These renal actions likely explain the hypertension in Kl Tg mice because elevations of FGF23 in Kl Tg mice were associated with increased NCC, decreased aldosterone levels, and higher blood pressure in Kl Tg mice. The possibility that the elevations of FGF23 are below a threshold necessary for exerting cardiotoxicity is not consistent with the hypertension in Kl Tg mice.
FGF23 is also purported to induce LVH by direct activation of FGFR4 in the myocardium through activation of PLC-γ hypertrophy signals (46) . Our findings suggest the lack of LVH in Kl Tg mice may be due to the newly discovered ability of mKL 135 or sKL 130 to inhibit FGF23 activation of PLC-γ signaling through FGFRs. FGF23 is reported to have low affinity for FGFRs in the absence of α-Klotho, but the seminal papers showing that mKL 135 is an obligate coreceptor necessary for FGF23 activation of FGFRs only investigated FSR2α-dependent ERK signaling and remarkably did not measure FGF23 activation of PLC-γ or PI3K/AKT signaling. Our in vitro studies confirmed FGF23 did not stimulate ERK in the absence of α-Klotho (1, 17) but also showed that FGF23 in the absence of mKL 135 or sKL 130 activates cardiotoxic PLC-γ pathways (46) . More important, we show that both mKL 135 and sKL 130 inhibited FGF23-induced PLC-γ and PI3K/AKT signaling. The ability of sKL to inhibit PLC-γ or PI3K/AKT signaling is a potentially novel observation in mammalian systems and is similar to the primordial functions of Klotho to inhibit tyrosine kinase receptor signaling in C. elegans, which lacks FGF23 expression (66) .
Our findings also are not in total agreement with the proposal that sKL 130 can substitute for mKL 135 as a cofactor in FGF23 activation of FGFRs. We found quantitative differences between sKL 130 and mKL 135 effects to promote FGF23-induced ERK signaling, with mKL 135 having several-fold greater effects to promote ERK signaling. This suggests that the transmembrane and C-terminus of mKL 135 has additional conformational effects to regulate FGFR coupling to ERK.
The current 3D model of FGF23, FGFR1c, and sKL 130 interactions does not adequately explain the complexity of sKL 130 and mKL 135 effects to bias FGF23 signal transduction through FGFRs (3) . Indeed, the mechanisms whereby sKL inhibits FGF23-dependent PLC-γ and PI3K/AKT signaling remain to be explained. Recently sKL has been shown to bind with gangliosides containing α-2-3-sialyllactose in lipid rafts to inhibit PI3K signaling (19) , suggesting one possible mechanism. There are other mechanisms whereby sKL has cardioprotective effects that are independent from FGF23. These include disrupting IGF-1, TGF-β, or TNF-α signaling or effects on calcium-permeable TRPC6 channels that prevent development of LVH (20) . We also show that α-Klotho isoforms containing KL1 domain suppress both FGF23-and TNF-α-mediated NF-κB activation, indicating that the KL1 domain may be responsible for some of these FGF23-independent functions (1, 17, 18, (66) (67) (68) . Indeed, the KL1 domain of Klotho was reported to bind to retinoic acid inducible gene I to suppress NF-κB signaling (68) , and NF-κB activation was linked with many of life span regulators, including insulin/IGF-1, FOXO, SIRT, mTOR, and DNA damage (69, 70) . It has been reported that FGF23 stimulates TNF-α production (45) , and PLC-γ phosphorylation involves the activation of NF-κB signaling (71) . Additional studies are needed to explore the potential functional differences in sKL70 (KL1) and sKL130 (KL1 + KL2) proteins and their contribution to the increased longevity in Kl Tg mice.
Because excess α-Klotho confers cardiac and renal protection (72, 73) , we were surprised by the finding that transferring an Fgf23-null background onto Kl Tg mice did not improve survival compared to single Fgf23null and Kl Tg mice. Deficiency of α-Klotho leads to a shorter life span and multiple adverse effects resembling abnormalities caused by FGF23 deficiency (2, 10, 74, 75) . The loss of FGF23/FGFR/KL signaling must override the α-Klotho effects that are independent from FGF23 (1, 2) . FGF23's presence may be needed to observe the increased longevity phenotype in Kl Tg mice. The effect of FGF23 on longevity is often analyzed in a renal failure model, but the current experiments did not examine it in this condition.
Nevertheless, our findings provide additional insights into the pathophysiology of FGF23 and α-Klotho by suggesting that the levels of sKL as well as the tissue expression of mKL 135 , along with levels of circulating FGF23, may determine whether physiological or adverse effects are observed. For example, other studies show that angiotensin II can both enhance cardiac fibrosis (76) and attenuate cardiac hypertrophy in Kl Tg mice (59) , possibly due to different roles of membrane and soluble α-Klotho isoforms. Typically, models of FGF23-induced LVH have suppression of α-Klotho (77), suggesting that cardiotoxicity requires elevated FGF23 and reduced sKL. In Kl Tg mice, the ectopic expression of mKl 135 in the heart or circulating sKL acting as an "on demand" coreceptor may have attenuated FGF23 cardiotoxicity through reducing PLC-γ-dependent cardiac hypertrophy pathways (25, 78) .
In conclusion, α-Klotho's effects to extend lifespan occurs in the presence of increased FGF23. Further, our findings indicate that FGF23's physiological functions and toxicity can be differentially modulated by the single-pass 135-kDa transmembrane mKL 135 and circulating ~130-kDa sKL 130 isoform through stimulation of ERK and inhibition of PLC and PI3K/AKT signaling pathways downstream of FGFRs. The ability of α-Klotho to regulate FGF23 expression and its KL1 isoforms to modify FGF23 activation of FGFR signaling pathways provides a new mechanistic understanding of the b1-kidney-cardiac axis regulating mineral and cardiovascular homeostasis. In addition, pharmacological elevation of sKL isoforms may offer a potential approach to attenuate toxicities mediated by excess FGF23 and accentuate FGF23-independent effects of α-Klotho.
Methods
Animal breeding and genotyping. We obtained Kl Tg mice from Makoto Kuro-o (1). These mice overexpress transmembrane Klotho form (mKl 135 ) under the control of the hEF1a. The Fgf23-heterozygous mice (Fgf23 +/-) were created by our laboratory as described previously (53) . These mice were bred and maintained on a C57BL/6J background. The mice were anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg) for a bone densitometry scan, and mice not useful for experimental purposes were sacrificed by CO 2 inhalation plus cervical dislocation. To examine whether overexpression of mKl 135 rescues the phenotypes of Fgf23-null mice, we created double-heterozygous Kl Tg Fgf23 +/mice. Then double-heterozygous Kl Tg Fgf23 +/mice were mated with Kl Tg Fgf23 +/mice to generate Fgf23 -/and Kl Tg Fgf23 -/mice, as well as Kl Tg and wild-type mice. These mice were used to count the percentage that survived and collect serum and tissue samples at 8 weeks of age for phenotypic analysis.
α-Klotho expression constructs. The human α-Klotho membrane (plasmid 17712) and secreted (plasmid 17713) forms were purchased from Addgene. Both human and mouse full-length α-Klotho membrane (mKL 135 ), fulllength α-Klotho without intra-cytoplasmic/transmembrane domain (sKL 130 ), sKL1 70 and sKL2 60 constructs that contain a signal sequence of the original full-length α-Klotho, and secreted α-Klotho (sKL 70 ) were gifts from Tami Rubinek and Ido Wolf (Sourasky Medical Center, Tel Aviv, Israel). For FGF23-mediated activation of the FGFR/KL complex, HEK293T cells (ATCC) were transiently transfected with either empty expression vector or various Klotho expression constructs along with the ERK luciferase reporter system (11) and Renilla a cell line optimal transfection kit according to the manufacturer's protocol (Amaxa Inc.). A total of 3.6 μg of plasmid DNAs was used for each electroporation. The transfected cells were plated in 12-well plates and harvested 32 hours after transfection. Cells were lysed in 100 μL of reporter lysis buffer (Promega). A luciferase assay (20 μL of cells lysed) was performed using a Synergy H4 Hybrid Multi-Mode Microplate Reader and Promega Dual-Luciferase Reporter Assay System.
Western blot analysis. Kidneys from wild-type and Kl Tg mice were homogenized into a fine powder in liquid nitrogen using a porcelain mortar and pestle. The powder was transferred into T-PER Tissue Protein Extraction Reagent with 1× Halt protease inhibitor (Thermo Fisher Scientific) and 1 mM phenylmethylsulfonyl fluoride (PMSF). After three 30-second sonications, samples were centrifuged at 13,000 g for 10 minutes, and supernatants were stored at -80°C until use. Similarly, HEK293T cells transfected with human mKL 135 , sKL 130 , sKL 70 , sKL1 70 , or sKL2 60 were lysed with 150 μL of M-PER Cell Protein Extraction Reagent (Pierce Biotechnology, Thermo Fisher Scientific) with 1× Halt protease inhibitor and 1 mM PMSF per well. After three 30-second sonications, whole-cell lysates were centrifuged at 13,000 g for 10 minutes, and supernatants were stored at -80°C until use. Protein concentrations of the supernatant were determined with a total protein assay kit (Bio-Rad). Equal quantities of protein were subjected to 4%-12% Bis-Tris gradient gels (Invitrogen, Thermo Fisher Scientific) and were analyzed with standard Western blot protocols (HRP-conjugated secondary antibodies from Santa Cruz Biotechnology [sc-2006] and ECL chemiluminescent immunodetection system from GE Healthcare Bio-Sciences). Anti-Klotho KL1 rat mAb (KM2076) and anti-Klotho KL2 rat mAb (KM2119) were purchased from TransGenic Inc. (85) . Anti-Klotho KL1 rat mAb (KL-234) was provided by Gwendalyn D. King at University of Alabama at Birmingham (USA) (86) . HA Tag mAb (26183-HRP) was purchased from Thermo Fisher Scientific. Anti-phospho-ERK1/2 (Thr202/Tyr204) (D13.14.4E, catalog 4370), anti-ERK1/2 (catalog 9102), anti-phospho-PLCγ1 (D25A9, catalog 8713), anti-PLCγ1 (catalog 2822), anti-phospho-Akt (D9E, catalog 4060), and anti-Akt (catalog 9272) were purchased from Cell Signaling Technologies. Anti-β-actin (sc-47778) antibody was purchased from Santa Cruz Biotechnology. The intensity of bands was quantified using ImageJ software.
Statistics. We evaluated differences between 2 groups by unpaired 2-tailed t test and multiple groups by 1-way ANOVA with Newman-Keuls multiple-comparisons test. All values are expressed as mean ± SD. All computations were performed using a commercial biostatistics software (Prism by GraphPad Software Inc.). P value less than 0.05 was considered significant.
Study approval. All animal research was conducted according to guidelines provided by the National Institutes of Health (NIH) and the Institute of Laboratory Animal Resources, National Research Council. The University of Tennessee Health Science Center's Animal Care and Use Committee approved all animal studies (protocol 18-111.0).
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